SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after announcing positive Phase 2 S-OLARIS trial results in axial spondyloarthritis, with its drug sonelokimab showing an 81% response rate and potential for disease modification, fueling expectations for a major re-rating and potential short squeeze ahead of its Investor Day.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohen's recent cryptic social media posts are driving intense speculation among investors about an imminent, monumental acquisition or strategic move, leveraging GameStop's substantial cash reserves. This dynamic fuels a fierce debate between ardent holders anticipating a massive short squeeze and skeptics citing ongoing price suppression and the absence of concrete company details.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to recent announcements of its advanced GaN and SiC power platforms aimed at next-gen AI data centers and its positioning within NVIDIA's AI ecosystem. The community is actively discussing the immense potential of its technology while simultaneously expressing significant concern over the absence of definitive, revenue-generating contracts amidst anticipation for its earnings call.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Escalating US-Iran tensions are a primary catalyst, leading the community to intensely debate the potential for military action and a subsequent surge in oil prices, positioning Exxon Mobil as a key beneficiary. This geopolitical focus, coupled with the company's strong production in regions like Guyana and strategic moves into carbon capture, is driving bullish sentiment despite some concerns about the stock's rapid ascent.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

The recent acquisition of Astria Therapeutics, integrating the late-stage HAE drug navenibart, is driving BioCryst's conversation, especially with new data presentations for navenibart and Orladeyo expected at a medical conference and upcoming earnings. The community is actively discussing the potential of these pipeline advancements against persistent concerns about the stock's valuation and significant short interest.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is trending sharply lower following a significant executive shake-up and weak financial guidance, leading the community to label it a "scam IPO" and deepen concerns amidst a challenging crypto market, though some still anticipate a turnaround driven by its newly licensed prediction market.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI is generating significant buzz as its community actively accumulates the token, driven by speculation around potential ETFs and its perceived status as the next-generation Layer 1 blockchain. Enthusiasts highlight its superior speed and efficiency compared to rivals, with many viewing current price levels as a prime buying opportunity.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending with strong community enthusiasm surrounding its anticipated BLA resubmission for deramiocel by the end of February, driving speculation for accelerated FDA approval and potential buyout interest, all while institutional ownership continues to increase.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for Bysanti, a new treatment for bipolar I disorder and schizophrenia, which was granted New Chemical Entity (NCE) status with patent protection extending to 2044. The community is actively discussing this as a major re-rating catalyst, anticipating significant institutional buying, and speculating on the drug's blockbuster potential alongside future pipeline developments.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC the metals company is trending as the community eagerly awaits the conclusion of the public comment period for its NOAA deep-sea mining permit, with strong bullish sentiment anticipating approval to secure critical minerals for national security and the energy transition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Analysts

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are currently covering the company, Marketbeat Ratings reports...

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

HC Wainwright Reduces Earnings Estimates for Adicet Bio

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Equities researchers at HC Wainwright decreased their FY2025 earnings per share estimates for Adicet Bio in a report released on Wednesday, January...

Adicet Bio (NASDAQ:ACET) Shares Pass Below 200-Day Moving Average - What's Next?

Adicet Bio (NASDAQ:ACET) Stock Crosses Below 200-Day Moving Average - What's Next...

Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Decline in Short Interest

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 642,724 shares, a drop...

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate...

Adicet Bio (NASDAQ:ACET) Sees Unusually-High Trading Volume - Still a Buy?

Adicet Bio (NASDAQ:ACET) Sees Strong Trading Volume - Should You Buy...

Adicet Bio (NASDAQ:ACET) Shares Up 4.5% - What's Next?

Adicet Bio (NASDAQ:ACET) Stock Price Up 4.5% - Should You Buy...

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update

Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 14,910,583...

Adicet Bio Stock Scheduled to Reverse Split on Tuesday, December 30th (NASDAQ:ACET)

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) shares are set to reverse split before the market opens on Tuesday, December 30th. The 1-16 reverse split was recently announced. The number of shares...

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$2.91	--	--	N/A
Q3 '25	-$0.29	-$4.64	-1500.24%	MISSED
Q2 '25	-$0.30	-$0.34	-11.89%	MISSED
Q1 '25	-$0.33	-$0.31	6.53%	BEAT
Q4 '24	-$0.36	-$0.32	10.28%	BEAT

ACET
Adicet Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ACET News

ACETAdicet Bio Inc